Solvay Pharmaceuticals has reported that the FDA approved Creon delayed-release capsules for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. Creon is reported
Novartis has reported that the FDA has approved Exforge HCT, claimed to be the only blood pressure treatment to combine three medications in a single pill. This FDA
Inspire Pharmaceuticals, a biopharmaceutical company, has initiated a Phase II program with AzaSite 1% to pursue a potential indication for the treatment of blepharitis, an ocular disease characterized
Ocimum Biosolutions, a genomics services company, has launched a new microarray-based test, for research use only, for the latest version of the H1N1 flu. The company has reported
Pulmatrix has reported that it will initiate a randomized, double-blind, placebo-controlled Phase Ib/IIa clinical trial of its novel inhaled therapy, PUR003, to demonstrate its effectiveness, safety and tolerability
Astellas Pharma Canada has reported encouraging results from a Canadian study which showed that patients with overactive bladder treated with solifenacin reported significantly lower incidence and severity of
The company has reported total revenues of $519.97 million for the first quarter of 2009 compared to $443.22 million for the first quarter of 2008. Frank Baldino Jr,
The first force-sensing ablation catheter developed worldwide, TactiCath gives physicians a real-time, objective measure of contact force during the catheter ablation procedure, said Endosense. The CE Mark allows
As part of the agreement, Ergomed will advance the oral formulation of tasidotin, developed by Genzyme, into clinical trials. In an earlier Phase II clinical trial sponsored by
By promoting the development, coordination and sharing of research resources and expertise, these awards expand research opportunities and increase the number of competitive investigators in 23 eligible states
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.